Morgan Stanley’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,285
| Closed | -$31.8K | – | 8510 |
|
|
2026
Q1 | $31.8K | Sell |
4,285
-1,400
| -25% | -$9.11K | ﹤0.01% | 6567 |
|
|
2025
Q4 | $35.8K | Sell |
5,685
-2,135
| -27% | -$12.5K | ﹤0.01% | 6531 |
|
|
2025
Q3 | $30.5K | Sell |
7,820
-873
| -10% | -$3.58K | ﹤0.01% | 6559 |
|
|
2025
Q2 | $39.8K | Buy |
8,693
+1,482
| +21% | +$6.35K | ﹤0.01% | 6429 |
|
|
2025
Q1 | $35.2K | Sell |
7,211
-13,398
| -65% | -$81.3K | ﹤0.01% | 6381 |
|
|
2024
Q4 | $138K | Sell |
20,609
-1,594
| -7% | -$11.9K | ﹤0.01% | 5927 |
|
|
2024
Q3 | $172K | Buy |
22,203
+21,490
| +3,014% | +$130K | ﹤0.01% | 5805 |
|
|
2024
Q2 | $4.28K | Sell |
713
-9,402
| -93% | -$71.5K | ﹤0.01% | 6885 |
|
|
2024
Q1 | $91.2K | Sell |
10,115
-41,742
| -80% | -$380K | ﹤0.01% | 6030 |
|
|
2023
Q4 | $491K | Buy |
51,857
+38,374
| +285% | +$337K | ﹤0.01% | 5620 |
|
|
2023
Q3 | $160K | Sell |
13,483
-35,650
| -73% | -$632K | ﹤0.01% | 5685 |
|
|
2023
Q2 | $1.2M | Buy |
49,133
+30,447
| +163% | +$793K | ﹤0.01% | 4726 |
|
|
2023
Q1 | $585K | Buy |
18,686
+2,320
| +14% | +$134K | ﹤0.01% | 5162 |
|
|
2022
Q4 | $1.15M | Buy |
16,366
+2,365
| +17% | +$175K | ﹤0.01% | 4793 |
|
|
2022
Q3 | $1.21M | Sell |
14,001
-1,907
| -12% | -$185K | ﹤0.01% | 4772 |
|
|
2022
Q2 | $1.31M | Sell |
15,908
-37,610
| -70% | -$3.32M | ﹤0.01% | 4834 |
|
|
2022
Q1 | $8.89M | Sell |
53,518
-90,751
| -63% | -$13M | ﹤0.01% | 3042 |
|
|
2021
Q4 | $24.1M | Buy |
144,269
+22,593
| +19% | +$2.55M | ﹤0.01% | 1974 |
|
|
2021
Q3 | $10.5M | Sell |
121,676
-36,379
| -23% | -$2.41M | ﹤0.01% | 2831 |
|
|
2021
Q2 | $8.58M | Buy |
158,055
+156,770
| +12,200% | +$8.9M | ﹤0.01% | 3164 |
|
|
2021
Q1 | $76K | Sell |
1,285
-2,114
| -62% | -$124K | ﹤0.01% | 6151 |
|
|
2020
Q4 | $177K | Buy |
3,399
+2,176
| +178% | +$121K | ﹤0.01% | 5651 |
|
|
2020
Q3 | $59K | Sell |
1,223
-1,113
| -48% | -$53.2K | ﹤0.01% | 5665 |
|
|
2020
Q2 | $122K | Buy |
2,336
+2,036
| +679% | +$103K | ﹤0.01% | 5308 |
|
|
2020
Q1 | $13K | Sell |
300
-2,678
| -90% | -$109K | ﹤0.01% | 5956 |
|
|
2019
Q4 | $120K | Buy |
2,978
+2,328
| +358% | +$71.7K | ﹤0.01% | 5590 |
|
|
2019
Q3 | $21K | Sell |
650
-6,848
| -91% | -$331K | ﹤0.01% | 5992 |
|
|
2019
Q2 | $578K | Buy |
7,498
+6,765
| +923% | +$1.05M | ﹤0.01% | 4528 |
|
|
2019
Q1 | $130K | Sell |
733
-1,113
| -60% | -$219K | ﹤0.01% | 5272 |
|
|
2018
Q4 | $436K | Buy |
1,846
+711
| +63% | +$174K | ﹤0.01% | 4868 |
|
|
2018
Q3 | $243K | Buy |
+1,135
| New | +$198K | ﹤0.01% | 5360 |
|
Morgan Stanley's KZR Position: Q2 2026 in Review
Morgan Stanley sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 4,285 shares — an estimated $31.8K sold.
Morgan Stanley first reported a position in KZR in Q3 2018 and held it in 31 quarters. The position peaked at $24.1M in Q4 2021. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Morgan Stanley reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Morgan Stanley sold 4,285 Kezar Life Sciences shares in Q2 2026, an estimated $31.8K.
- Morgan Stanley first reported a position in Kezar Life Sciences in Q3 2018 and held it in 31 quarters.
- Morgan Stanley's Kezar Life Sciences position peaked at $24.1M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.